GT Biopharma Investor Relations Material
Latest events
Q1 2025
15 May, 2025
Q4 2024
21 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GT Biopharma Inc
Access all reports
GT Biopharma Inc. is a biotechnology company focused on developing immuno-oncology therapies for cancer treatment. The company specializes in TriKE (Tri-specific Killer Engager) technology, which is designed to enhance the ability of natural killer (NK) cells to target and destroy cancer cells. GT Biopharma’s pipeline includes investigational treatments for hematologic malignancies and solid tumors. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.
Key slides for GT Biopharma Inc
Corporate Presentation
GT Biopharma Inc
Corporate Presentation
GT Biopharma Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
GTBP
Country
🇺🇸 United States